A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Protocol: 
AAAR0804
Phase: 
I

A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

The purpose of this study is to test the safety and tolerability of an experimental drug called MTIG7192A (also known as anti-TIGIT antibody) at different dose levels to find out what effects, good or bad, MTIG7192A has on you and your cancer. This study is composed of two parts: a Phase Ia study and a Phase Ib study. The Phase Ia study will test the safety and tolerability of an experimental drug called MTIG7192A alone. The Phase Ib study will test the safety and tolerability of MTIG7192A combined with atezolizumab, another experimental cancer immunotherapy drug.

Are you Eligible? (Inclusion Criteria)

1. Patients must have a locally advanced or metastatic solid tumor (Bladder, Head
and Neck, Ovarian, Kidney, Lung, Melanoma) that continues to grow despite
standard therapy.

2. Patients must be in good physical shape. This means that patients must be able
to walk, care for themselves, and do light physical activities such as light
housework or office work.

3. This study is for patients age 18 or older

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States